NASDAQ:GWPH - GW Pharmaceuticals PLC- Stock Price, Forecast & News

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

GW Pharmaceuticals PLC- (NASDAQ:GWPH) released its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.39. The biopharmaceutical company had revenue of $90.97 million for the quarter, compared to the consensus estimate of $86.84 million. GW Pharmaceuticals PLC- had a negative return on equity of 23.04% and a negative net margin of 26.80%. View GW Pharmaceuticals PLC-'s Earnings History.

GW Pharmaceuticals PLC- is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for GW Pharmaceuticals PLC-.

12 Wall Street analysts have issued 1-year price objectives for GW Pharmaceuticals PLC-'s stock. Their forecasts range from $134.00 to $238.00. On average, they expect GW Pharmaceuticals PLC-'s share price to reach $198.80 in the next twelve months. This suggests a possible upside of 75.0% from the stock's current price. View Analyst Price Targets for GW Pharmaceuticals PLC-.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GW Pharmaceuticals PLC-.

News headlines about GWPH stock have been trending positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GW Pharmaceuticals PLC- earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 5,760,000 shares, an increase of 5.5% from the November 28th total of 5,460,000 shares. Based on an average daily trading volume, of 783,300 shares, the days-to-cover ratio is currently 7.4 days. Currently, 18.8% of the shares of the company are short sold. View GW Pharmaceuticals PLC-'s Current Options Chain.

Some companies that are related to GW Pharmaceuticals PLC- include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and Dr.Reddy's Laboratories (RDY).

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Aurora Cannabis (ACB), Cronos Group (CRON), Tesla (TSLA), Zynerba Pharmaceuticals (ZYNE) and GW Pharmaceuticals (GWP).

GW Pharmaceuticals PLC-'s stock is owned by many different of institutional and retail investors. Top institutional investors include M&G Investment Management Ltd. (2.80%), California Public Employees Retirement System (0.21%), AdvisorShares Investments LLC (0.08%), Rothschild Investment Corp IL (0.06%), Janney Montgomery Scott LLC (0.04%) and Independent Investors Inc. (0.03%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Institutional Ownership Trends for GW Pharmaceuticals PLC-.

GWPH stock was sold by a variety of institutional investors in the last quarter, including Exane Derivatives, Steward Partners Investment Advisory LLC, Horrell Capital Management Inc. and NEXT Financial Group Inc. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

GWPH stock was purchased by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., AdvisorShares Investments LLC, Independent Investors Inc., California Public Employees Retirement System, Landsberg Bennett & Dubbaneh LLC, Investors Financial Group LLC, Dupont Capital Management Corp and Janney Montgomery Scott LLC. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GWPH stock can currently be purchased for approximately $113.57.

GW Pharmaceuticals PLC- has a market capitalization of $3.51 billion and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-79,880,000.00 in net income (profit) each year or ($10.56) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe.View Additional Information About GW Pharmaceuticals PLC-.

The official website for GW Pharmaceuticals PLC- is http://www.gwpharm.com/.

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]